Sanofi-Aventis Recherche & Developpement — Sponsor Intelligence | 111 EU Trials

Filter these 111 trials by condition, phase, country and more.

Open in Search →

111 Registered trials

43 Recruiting

64 Completed trials

25 Countries active

75 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 42 Phase II/III: 2 Phase II: 40 Phase I/II: 6 Phase IV: 2 Phase I: 5 Phase I (Other): 8 Phase I (FiH): 4 Other: 1 Other: 1

Oversight events:

1 temporary halt 3 unexpected events 1 corrective measure across 5 trials

View oversight register →

100%

64 of 64 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Dermatitis atopic 9 Multiple sclerosis 6 Plasma cell myeloma refractory 6 Asthma 6 Chronic rhinosinusitis with nasal polyps 5 Chronic obstructive pulmonary disease 5 Colitis ulcerative 5 Crohn´s disease 4 Plasma cell myeloma 3 Rheumatoid arthritis 2 Autoimmune haemolytic anaemia 2 Clinical trial participant 2

Top IMPs

ISATUXIMAB 10 AMLITELIMAB 9 DEXAMETHASONE 9 ITEPEKIMAB 9 FREXALIMAB 6 DUPILUMAB 5 RILIPRUBART 5 RILZABRUTINIB 5 DEXAMETHASONE SODIUM PHOSPHATE PH. EUR. 4 DUVAKITUG 4 LUNSEKIMIG 4 BALINATUNFIB 3

All trials — page 2

111 total

Brivekimig for the treatment of moderate to severe hidradenitis suppurativa Recruiting

2025-522333-61-00 Phase II 9 countries
A study of belumosudil in children with chronic graft versus host disease (schoolROCK). Recruiting

2024-511508-18-00 Phase I/II 6 countries BELUMOSUDIL MESILATE
A study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with Stage 3 Type 1 Diab… Recruiting

2024-519494-19-00 Phase III 10 countries TEPLIZUMAB
A 52-week study of rilzabrutinib efficacy and safety compared to placebo in adults diagnosed with IgG4-related disease Recruiting

2025-521398-15-00 Phase III 8 countries
A study to investigate the efficacy and safety of SAR444336 in adults with microscopic colitis in clinical remission. Recruiting

2024-519495-83-00 Phase II 8 countries SAR444336
A study to investigate the efficacy and safety of rilzabrutinib in adult participants with Graves’ disease Recruiting

2025-521023-75-00 Phase II 3 countries RILZABRUTINIB
A study to investigate the efficacy and safety of brivekimig in adult participants with ulcerative colitis. Recruiting

2024-515241-41-00 Phase II 6 countries SAR442970
A study to investigate the efficacy, safety, and pharmacokinetics of oral rilzabrutinib compared with placebo in participants 18 years of ag… Recruiting

2024-517972-39-00 Phase III 11 countries RILZABRUTINIB
A study to investigate the safety and efficacy of SAR446523 injected subcutaneously in adult participants with relapsed/refractory myeloma Recruiting

2024-511667-28-00 Phase I 3 countries
A study to investigate efficacy and safety of SAR441566 in patients with ulcerative colitis Recruiting

2025-520705-12-00 Phase II 12 countries BALINATUNFIB
Study of lunsekimig (SAR443765) compared with placebo in adults with high-risk asthma Recruiting

2024-513959-33-00 Phase II 10 countries LUNSEKIMIG
A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease. Recruiting

2024-512633-32-00 Phase II 11 countries BALINATUNFIB
A first-in-human, dose escalation and dose expansion study of SAR445877 in adult participants with advanced solid tumors Recruiting

2023-507141-28-00 Phase I (FiH) 2 countries BEVACIZUMAB; CETUXIMAB; KD050
A study to evaluate the efficacy and safety of frexalimab, brivekimig or rilzabrutinib in participants aged 16 to 75 years with primary foca… Recruiting

2024-511775-15-00 Phase II 11 countries
A study to test the efficacy and safety of riliprubart against the usual treatment of intravenous immunoglobulin (IVIg) in people with chron… Recruiting

2023-508338-33-00 Phase III 13 countries RILIPRUBART
A study to test the effects and safety of riliprubart in people with chronic inflammatory demyelinating polyneuropathy (CIDP) for which the … Recruiting

2023-506503-26-00 Phase III 13 countries RILIPRUBART
A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting

2023-503631-18-01 Phase III 23 countries TERIFLUNOMIDE; TOLEBRUTINIB
Frexalimab in preservation of endogenous insulin secretion compared to placebo in adults, adolescents and children on top of Insulin therapy… Recruiting

2022-500531-36-00 Phase II 13 countries
A study to test how effective belumosudil tablets are for treating adult participants with chronic lung allograft dysfunction Recruiting

2023-503462-23-00 Phase III 14 countries BELUMOSUDIL MESILATE
Efficacy and safety of subcutaneous dupilumab for the treatment of adult participants with chronic pruritus of unknown origin (CPUO) Recruiting

2023-508879-36-00 Phase III 6 countries DUPILUMAB
Isatuximab in combination with novel agents in RRMM – Master protocol and control arm Recruiting

2024-514988-25-00 Phase I/II 6 countries DEXAMETHASONE; ISATUXIMAB; POMALIDOMIDE
Isatuximab in combination with SAR445761 (belumosudil) and dexamethasone in relapsed or refractory multiple myeloma Recruiting

2024-514992-16-00 Phase I/II 6 countries BELUMOSUDIL MESILATE; DEXAMETHASONE; ISATUXIMAB
Isatuximab in combination with evorpacept and dexamethasone in RRMM Recruiting

2024-514993-38-00 Phase I/II 6 countries DEXAMETHASONE; EVORPACEPT; ISATUXIMAB
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents with Systemic Juvenile Idiopathic Arthritis (sJIA) Recruiting

2024-512701-11-00 Phase II 11 countries SARILUMAB

Showing 25–48 of 111 trials

← All sponsors A–Z